Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight loss results comparable to those of popular GLP-1 injectables like ...

The drug, amycretin, works by replicating two hunger hormones — amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that is ...

Novo Nordisk released data Wednesday showing that patients taking its new medication, a pill known as amycretin, lost up to 13% of their body weight after 12 weeks, with mild to moderate side effects.

Share on Pinterest Novo Nordisk’s new weight loss pill, amycretin, has had promising results in an early clinical trial. Image credit: SERGEI GAPON/Getty Images. Amycretin, a new weight loss ...

Amycretin trial showed weight loss of 9.7% to 22% over 36 weeks at varying doses, compared to weight gain with placebo. Common side effects were mild-to-moderate gastrointestinal issues ...

Novo Nordisk is developing a weight loss pill. In the early stage trial, Novo evaluated how patients fared when taking one or two 50 mg amycretin pills a day or an inert placebo. Patients taking ...

Amycretin mimics the actions of glucagon-like peptide-1 (GLP-1) and amylin, hormones that play a role in reducing blood sugar ...

Novo Nordisk's weight loss candidate in question is called amycretin. The company is developing an oral and a subcutaneous version of this medicine. Amycretin is a GLP-1 agonist, but it also ...

People who took the drug amycretin lost up to 13% of their body weight over three months, according to early clinical trial results presented at the European Association for the Study of Diabetes ...

People who took the drug amycretin lost up to 13% of their body weight over three months, according to early clinical trial results presented at the European Association for the Study of Diabetes ...

Results of early-stage trial of injectable amycretin Novo shares jump as much as 13% to a one-month high Novo faces strong competition in obesity drugs from Eli Lilly Jan 24 (Reuters ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety ...